JP2019516711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516711A5 JP2019516711A5 JP2018560520A JP2018560520A JP2019516711A5 JP 2019516711 A5 JP2019516711 A5 JP 2019516711A5 JP 2018560520 A JP2018560520 A JP 2018560520A JP 2018560520 A JP2018560520 A JP 2018560520A JP 2019516711 A5 JP2019516711 A5 JP 2019516711A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- riluzole
- checkpoint inhibitor
- drug according
- msr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 13
- 229960004181 riluzole Drugs 0.000 claims 13
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 10
- 229940000425 combination drug Drugs 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 229940124650 anti-cancer therapies Drugs 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173334A JP7493569B2 (ja) | 2016-05-20 | 2022-10-28 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339433P | 2016-05-20 | 2016-05-20 | |
| US62/339,433 | 2016-05-20 | ||
| PCT/US2017/033688 WO2017201501A1 (en) | 2016-05-20 | 2017-05-19 | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173334A Division JP7493569B2 (ja) | 2016-05-20 | 2022-10-28 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516711A JP2019516711A (ja) | 2019-06-20 |
| JP2019516711A5 true JP2019516711A5 (https=) | 2020-06-11 |
| JP7169195B2 JP7169195B2 (ja) | 2022-11-10 |
Family
ID=60326148
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560520A Active JP7169195B2 (ja) | 2016-05-20 | 2017-05-19 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
| JP2018560528A Active JP7224186B2 (ja) | 2016-05-20 | 2017-05-19 | 癌を処置するためのグルタミン酸調節剤と免疫療法の併用 |
| JP2022150358A Active JP7653398B2 (ja) | 2016-05-20 | 2022-09-21 | 癌を処置するためのグルタミン酸調節剤と免疫療法の併用 |
| JP2022173334A Active JP7493569B2 (ja) | 2016-05-20 | 2022-10-28 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560528A Active JP7224186B2 (ja) | 2016-05-20 | 2017-05-19 | 癌を処置するためのグルタミン酸調節剤と免疫療法の併用 |
| JP2022150358A Active JP7653398B2 (ja) | 2016-05-20 | 2022-09-21 | 癌を処置するためのグルタミン酸調節剤と免疫療法の併用 |
| JP2022173334A Active JP7493569B2 (ja) | 2016-05-20 | 2022-10-28 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US12383619B2 (https=) |
| EP (3) | EP3458053B1 (https=) |
| JP (4) | JP7169195B2 (https=) |
| KR (2) | KR102369735B1 (https=) |
| CN (2) | CN109890387B (https=) |
| AU (2) | AU2017266951B2 (https=) |
| CA (1) | CA3025019A1 (https=) |
| CY (1) | CY1124999T1 (https=) |
| DK (2) | DK4019019T3 (https=) |
| EA (1) | EA201892587A1 (https=) |
| ES (3) | ES2981830T3 (https=) |
| FI (1) | FI4019019T3 (https=) |
| HR (2) | HRP20240617T1 (https=) |
| HU (2) | HUE058184T2 (https=) |
| IL (2) | IL292302B2 (https=) |
| LT (2) | LT3458053T (https=) |
| MX (2) | MX2018013868A (https=) |
| PH (1) | PH12018502409A1 (https=) |
| PL (2) | PL4019019T3 (https=) |
| PT (2) | PT4019019T (https=) |
| RS (2) | RS62935B1 (https=) |
| SG (1) | SG11201809669RA (https=) |
| SI (2) | SI4019019T1 (https=) |
| SM (1) | SMT202400174T1 (https=) |
| WO (2) | WO2017201501A1 (https=) |
| ZA (1) | ZA201807398B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9725427B2 (en) * | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| EP3359150A4 (en) | 2015-10-05 | 2019-11-06 | Calithera Biosciences, Inc. | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS |
| LT3458053T (lt) * | 2016-05-20 | 2022-02-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui |
| JP7158104B2 (ja) | 2016-07-15 | 2022-10-21 | ビラクタ セラピューティクス，インク． | Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤 |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| JP7258747B2 (ja) * | 2016-10-28 | 2023-04-17 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｐｄ－１抗体を用いた尿路上皮癌の処置方法 |
| DK3551660T5 (da) | 2016-12-07 | 2024-09-02 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| US20210177841A1 (en) * | 2017-11-03 | 2021-06-17 | Calithera Biosciences, Inc. | Conjoint therapy with glutaminase inhibitors |
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| TW202000205A (zh) | 2018-02-21 | 2020-01-01 | 美商Ａｉ治療公司 | 使用阿吡莫德與麩胺酸性劑的組合治療 |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| MX2021000515A (es) * | 2018-07-22 | 2021-06-08 | Biohaven Therapeutics Ltd | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. |
| EP3914266A4 (en) * | 2019-01-24 | 2022-12-07 | University of Cincinnati | AUTOLOGOUS TUMORORGANOID AND IMMUNE CELL COCULTURES AND METHODS FOR USE AS PREDICTIVE MODELS FOR TREATMENT OF PANCREA CANCER |
| CA3141405A1 (en) * | 2019-06-12 | 2020-12-17 | H. Charles Manning | Amino acid transport inhibitors and the uses thereof |
| CN110646557A (zh) * | 2019-10-12 | 2020-01-03 | 北京航空航天大学 | 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途 |
| EP4121117B1 (en) * | 2020-03-17 | 2025-10-08 | Ohio State Innovation Foundation | Designer extracellular vesicles for treating excitotoxicity |
| KR102441650B1 (ko) * | 2020-07-31 | 2022-09-08 | 서울대학교병원 | 다중약물 화학요법에 있어서 항암제의 유효 용량 정보의 제공 방법 |
| WO2022197767A1 (en) * | 2021-03-17 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for improving survival in lung cancer patients via ketamine oncoprotection |
| WO2023003972A1 (en) * | 2021-07-21 | 2023-01-26 | Viracta Subsidiary, Inc. | Cancer treatment combinations |
| TW202406539A (zh) * | 2022-04-21 | 2024-02-16 | 大陸商北京加科思新藥研發有限公司 | 藥物組合及其用途 |
| CN116492322A (zh) * | 2023-05-10 | 2023-07-28 | 徐州医科大学 | 小分子阻滞剂mem在制备治疗肿瘤药物的应用 |
| CN119174765A (zh) * | 2024-09-04 | 2024-12-24 | 复旦大学附属中山医院 | Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA209066A (en) | 1921-03-01 | Tschirner Frederick | Conversion of potassium to soluble state | |
| US135A (en) | 1837-03-03 | Jesse j | ||
| US7812A (en) | 1850-12-03 | Nail-plate feeder and turner | ||
| US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| ATE208615T1 (de) | 1993-07-09 | 2001-11-15 | Scherer Corp R P | Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| RU2192281C2 (ru) | 1996-10-11 | 2002-11-10 | Бристол-Маерс Сквибб Компани | Способы и композиции для иммуномодуляции |
| WO1998036738A1 (en) | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| PT1001748E (pt) | 1997-07-25 | 2006-08-31 | Alpex Pharma Sa | Um processo para a preparacao de um granulado adequado para a preparacao de comprimidos rapidamente desintegraveis na boca |
| IL143197A0 (en) | 1998-11-20 | 2002-04-21 | Rtp Pharma Inc | Dispersible phospholipid stabilized microparticles |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| BR0012196A (pt) | 1999-06-25 | 2002-03-19 | Genentech Inc | Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| ES2292848T3 (es) | 2001-10-12 | 2008-03-16 | Elan Pharma International Limited | Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada. |
| AU2003211051A1 (en) | 2002-02-13 | 2003-09-04 | Michael K. Weibel | Drug dose-form and method of manufacture |
| EP2298346A3 (en) | 2002-03-04 | 2011-11-16 | Imclone LLC | Human antibodies specific to kdr and uses thereof |
| JP2006500921A (ja) | 2002-07-30 | 2006-01-12 | ブリストル−マイヤーズ スクイブ カンパニー | ヒト４−１ｂｂに対するヒト化抗体 |
| HRP20120845T1 (hr) | 2003-07-02 | 2012-11-30 | Innate Pharma | Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju |
| HRP20170342T1 (hr) | 2003-07-24 | 2017-05-19 | Innate Pharma S.A. | Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2006003179A2 (en) | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
| ES2355923T3 (es) | 2004-08-26 | 2011-04-01 | Pfizer, Inc. | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa. |
| DE602005020465D1 (de) | 2004-08-26 | 2010-05-20 | Pfizer | Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer |
| CN101102791B (zh) | 2004-11-18 | 2011-12-14 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
| CN101103043A (zh) | 2005-01-06 | 2008-01-09 | 诺和诺德公司 | Kir结合剂和使用其的方法 |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP1744020A1 (de) | 2005-07-14 | 2007-01-17 | Siemens Aktiengesellschaft | Verfahren zum Starten einer Dampfturbinenanlage |
| CN101300272B (zh) | 2005-10-14 | 2013-09-18 | 依奈特制药公司 | 用于治疗增生性病症的组合物和方法 |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| DK1963302T3 (da) | 2005-12-05 | 2013-04-02 | Pfizer Prod Inc | Polymorfer af en C-MET/HGFR-inhibitor |
| PL1959955T3 (pl) | 2005-12-05 | 2011-04-29 | Pfizer Prod Inc | Sposób traktowania nieprawidłowego wzrostu komórek |
| BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| CN105037549B (zh) | 2007-01-11 | 2018-09-28 | 诺和诺德公司 | 抗-kir抗体、制剂及其应用 |
| JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用 |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2170282A4 (en) | 2007-06-27 | 2014-11-05 | Hanmi Pharm Ind Co Ltd | METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| ES2526355T3 (es) | 2007-10-01 | 2015-01-09 | Bristol-Myers Squibb Company | Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos |
| CA2705152C (en) | 2007-11-09 | 2016-10-11 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
| CL2008003526A1 (es) | 2007-11-30 | 2010-01-11 | Medarex Inc | Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer. |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US8613937B2 (en) | 2008-10-31 | 2013-12-24 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8414356B2 (en) | 2008-10-31 | 2013-04-09 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| EP2367553B1 (en) | 2008-12-05 | 2017-05-03 | Novo Nordisk A/S | Combination therapy to enhance nk cell mediated cytotoxicity |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| EA201690310A1 (ru) | 2010-04-13 | 2016-12-30 | Селлдекс Терапьютикс Инк. | Антитела, связывающие cd27 человека, и их применение |
| TWI500617B (zh) | 2010-05-31 | 2015-09-21 | Ono Pharmaceutical Co | Purine ketone derivatives |
| BR112013009086A2 (pt) * | 2010-10-13 | 2016-07-26 | Mustafa Bilgin Ali Djamgoz | tratamento de câncer/inibição de metástase |
| EP2643350A4 (en) | 2010-11-22 | 2015-01-07 | Innate Pharma Sa | TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| ES2765874T3 (es) | 2011-05-25 | 2020-06-11 | Innate Pharma Sa | Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios |
| RU2014102935A (ru) | 2011-08-02 | 2015-09-10 | Пфайзер Инк. | Кризотиниб для применения в лечении рака |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
| CN104039320B (zh) | 2011-11-09 | 2019-10-15 | 百时美施贵宝公司 | 血液恶性肿瘤用抗-cxcr4抗体的治疗 |
| US10864271B2 (en) * | 2012-02-15 | 2020-12-15 | Rutgers, The State University Of New Jersey | Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation |
| US9725427B2 (en) * | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR101566539B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도 |
| US10357497B2 (en) * | 2012-06-23 | 2019-07-23 | Biohaven Pharmaceutical Holding Company Limited | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| PL2904011T3 (pl) | 2012-10-02 | 2018-01-31 | Bristol Myers Squibb Co | Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| JP6595458B2 (ja) | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| CN103536594A (zh) * | 2013-10-21 | 2014-01-29 | 江苏亚虹医药科技有限公司 | G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途 |
| EA201690746A1 (ru) | 2013-10-25 | 2016-12-30 | Фармасайкликс Элэлси | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии |
| SI3148579T1 (sl) | 2014-05-28 | 2021-07-30 | Agenus Inc. | Proti GITR antitelesa in postopki z njihovo uporabo |
| RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| US10392444B2 (en) * | 2014-08-08 | 2019-08-27 | Oncoquest, Inc. | Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer |
| US20160073759A1 (en) * | 2014-09-15 | 2016-03-17 | Beauty Solutions Agency Inc. | Nail covering |
| US11236139B2 (en) * | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
| ES2843324T3 (es) * | 2014-11-18 | 2021-07-16 | Maximum Fidelity Surgical Simulations Llc | Reconstitución de la circulación post mortem |
| US20160140879A1 (en) * | 2014-11-19 | 2016-05-19 | David Hananel | Anatomically correct movement or deformation of simulated bodily structures |
| US11911369B2 (en) * | 2015-03-03 | 2024-02-27 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole and their method of use |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| KR20250004095A (ko) | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| US20190054090A1 (en) | 2015-10-01 | 2019-02-21 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| LT3458053T (lt) | 2016-05-20 | 2022-02-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui |
-
2017
- 2017-05-19 LT LTEPPCT/US2017/033688T patent/LT3458053T/lt unknown
- 2017-05-19 HR HRP20240617TT patent/HRP20240617T1/hr unknown
- 2017-05-19 US US16/302,270 patent/US12383619B2/en active Active
- 2017-05-19 MX MX2018013868A patent/MX2018013868A/es unknown
- 2017-05-19 KR KR1020187036485A patent/KR102369735B1/ko active Active
- 2017-05-19 HU HUE17800310A patent/HUE058184T2/hu unknown
- 2017-05-19 PL PL21207246.6T patent/PL4019019T3/pl unknown
- 2017-05-19 EP EP17800310.9A patent/EP3458053B1/en active Active
- 2017-05-19 DK DK21207246.6T patent/DK4019019T3/da active
- 2017-05-19 HU HUE21207246A patent/HUE066655T2/hu unknown
- 2017-05-19 JP JP2018560520A patent/JP7169195B2/ja active Active
- 2017-05-19 IL IL292302A patent/IL292302B2/en unknown
- 2017-05-19 SG SG11201809669RA patent/SG11201809669RA/en unknown
- 2017-05-19 RS RS20220165A patent/RS62935B1/sr unknown
- 2017-05-19 CN CN201780044939.XA patent/CN109890387B/zh active Active
- 2017-05-19 SI SI201731511T patent/SI4019019T1/sl unknown
- 2017-05-19 DK DK17800310.9T patent/DK3458053T3/da active
- 2017-05-19 JP JP2018560528A patent/JP7224186B2/ja active Active
- 2017-05-19 SM SM20240174T patent/SMT202400174T1/it unknown
- 2017-05-19 US US16/302,284 patent/US11400155B2/en active Active
- 2017-05-19 AU AU2017266951A patent/AU2017266951B2/en active Active
- 2017-05-19 ES ES21207246T patent/ES2981830T3/es active Active
- 2017-05-19 HR HRP20220237TT patent/HRP20220237T1/hr unknown
- 2017-05-19 RS RS20240502A patent/RS65474B1/sr unknown
- 2017-05-19 WO PCT/US2017/033688 patent/WO2017201501A1/en not_active Ceased
- 2017-05-19 PT PT212072466T patent/PT4019019T/pt unknown
- 2017-05-19 CA CA3025019A patent/CA3025019A1/en active Pending
- 2017-05-19 ES ES17800310T patent/ES2905823T3/es active Active
- 2017-05-19 KR KR1020227006275A patent/KR102525527B1/ko active Active
- 2017-05-19 EA EA201892587A patent/EA201892587A1/ru unknown
- 2017-05-19 FI FIEP21207246.6T patent/FI4019019T3/fi active
- 2017-05-19 SI SI201731061T patent/SI3458053T1/sl unknown
- 2017-05-19 PL PL17800310T patent/PL3458053T3/pl unknown
- 2017-05-19 CN CN202210573206.8A patent/CN115350263A/zh active Pending
- 2017-05-19 LT LTEP21207246.6T patent/LT4019019T/lt unknown
- 2017-05-19 EP EP21207246.6A patent/EP4019019B1/en active Active
- 2017-05-19 PT PT178003109T patent/PT3458053T/pt unknown
- 2017-05-19 EP EP17800311.7A patent/EP3458054B1/en active Active
- 2017-05-19 ES ES17800311T patent/ES2912131T3/es active Active
- 2017-05-19 WO PCT/US2017/033690 patent/WO2017201502A1/en not_active Ceased
-
2018
- 2018-11-05 ZA ZA2018/07398A patent/ZA201807398B/en unknown
- 2018-11-07 IL IL262849A patent/IL262849B/en unknown
- 2018-11-12 MX MX2022010377A patent/MX2022010377A/es unknown
- 2018-11-15 PH PH12018502409A patent/PH12018502409A1/en unknown
-
2021
- 2021-08-25 AU AU2021221560A patent/AU2021221560B2/en active Active
-
2022
- 2022-02-16 CY CY20221100131T patent/CY1124999T1/el unknown
- 2022-08-01 US US17/878,121 patent/US20230310595A1/en active Pending
- 2022-09-21 JP JP2022150358A patent/JP7653398B2/ja active Active
- 2022-10-28 JP JP2022173334A patent/JP7493569B2/ja active Active
-
2025
- 2025-08-12 US US19/297,799 patent/US20250360208A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516711A5 (https=) | ||
| Bedke et al. | Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2019536805A5 (https=) | ||
| JP2017504611A5 (https=) | ||
| FI3377534T3 (fi) | Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää | |
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| JP2018508593A5 (https=) | ||
| Nemunaitis et al. | Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors | |
| JP2019517511A5 (https=) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2014132009A5 (https=) | ||
| JP2016529285A5 (https=) | ||
| JP2018508516A5 (https=) | ||
| JP2013507415A5 (https=) | ||
| Yoon et al. | Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib | |
| JP2014513089A5 (https=) | ||
| JP2016525097A5 (https=) | ||
| JP2019532047A5 (https=) | ||
| CA2922684A1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
| Ramaswamy et al. | A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors | |
| JP2019508476A5 (https=) | ||
| Denlinger et al. | A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers | |
| Suder et al. | A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours | |
| JP2019530706A5 (https=) |